IOF World Congress on Osteoporosis

Back to Homepage


IOF World Congress on Osteoporosis News bulletin #14 April 30, 2002

EXPERTS TO PROVIDE DAILY PRESS BRIEFINGS

Experts will brief journalists daily on the latest research developments presented at the IOF World Congress on Osteoporosis.

Saturday May 11, 2002 15.30-16.30
Theme: Pathophysiology and nutrition
Chairman: Peter Burckhardt
Speakers:

P. Ammann (O5 – Session I) PROTEIN UNDERNUTRITION-INDUCED BONE RESORPTION IS DEPENDENT ON TUMOR NECROSIS FACTOR ALFA (TNF)

M. Lehtonen-Veromaa (O4 – Session I) VITAMIN D AND ATTAINMENT OF PEAK BONE MASS AMONG PERIPUBERTAL FINNISH GIRLS: A 3-YEAR PROSPECTIVE STUDY

P.J. Meunier (O35 – Session VII) A CALCIUM-VITAMIN D3 COMBINED SUPPLEMENTATION IS COST-SAVING FOR PREVENTING HIP FRACTURES IN INSTITUTIONALISED ELDERLY WOMEN : AN ECONOMIC EVALUATION FROM THE PERSPECTIVE OF SEVEN EUROPEAN COUNTRIES (BELGIUM, FRANCE, GERMANY, THE NETHERLANDS, SPAIN, SWEDEN, UNITED KINGDOM)

S. Boonen (O16 – Session III) COLLES' FRACTURE AND SUBSEQUENT HIP-FRACTURE RISK IN MEN: A META-ANALYSIS

Sunday May 12, 2002 13.00-14.00
Theme: Latest developments in treatment
Chairman: Rene Rizzoli
Speakers:

P.D. Delmas (O37 – Session VII) ORAL IBANDRONATE SIGNIFICANTLY REDUCES FRACTURE RISK IN POSTMENOPAUSAL OSTEOPOROSIS WHEN ADMINISTERED DAILY OR WITH A UNIQUE DRUG-FREE INTERVAL: RESULTS FROM A PIVOTAL PHASE III STUDY

E. Orwoll (O39 – Session VII) EFFECTS OF BASELINE VERTEBRAL BMD, AGE, PREVIOUS VERTEBRAL FRACTURE, FREE TESTOSTERONE, ESTRADIOL, SMOKING AND ALCOHOL ON THE RESPONSE TO TERIPARATIDE INJECTION rhPTH[1-34] IN MEN WITH OSTEOPOROSIS

P.J. Meunier (O45 – Session VIII) STRONTIUM RANELATE REDUCES THE VERTEBRAL FRACTURE RISK IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS

Monday May 13, 2002 13.00-14.00
Theme: Diagnosis prediction and risk factors
Chairman: Jean-Yves Reginster
Speakers:

D.C. Bauer (O44 – Session VIII) REDUCTION IN BONE TURNOVER PREDICTS HIP, NON-SPINE, AND VERTEBRAL FRACTURE IN ALENDRONATE TREATED WOMEN: THE FRACTURE INTERVENTION TRIAL

J.D. Adachi (O32 – Session VI) ONCE-A-WEEK (35 mg) RISEDRONATE IS AS EFFECTIVE AS DAILY (5 mg)

S. Adami (O40 – Session VII) EFFECTS OF CYCLIC ADMINISTRATION OF INTRAVENOUS NERIDRONATE ON BONE DENSITY IN ADULT PATIENTS WITH OSTEOGENESIS IMPERFECTA

Tuesday May 14, 2002 13.00-14.00
Theme: Recent developments in osteo-arthritis
Chairman: Jean-Yves Reginster
Speakers:

Jean-Pierre Pelletier (OA5) THERAPEUTIC TARGETS IN OSTEOARTHRITIS

Marc Hochberg (OA6) ROLE OF SELECTIVE INHIBITORS OF CYCLO-OXYGENASE II IN THE MANAGEMENT OF OSTEOARTHRITIS

Jean-Yves Reginster (OA7) STRUCTURE-MODIFYING DRUGS IN OSTEOARTHRITIS

Exclusive Journalists' Briefings Available

IOF board member Ego Seeman, editor of Progress in Osteoporosis, has prepared two briefings that put the WCO research into context of bigger stories. This paper is available on the IOF website at:
http://www.osteofound.org/wco/2002/press_center.php

These briefings may help journalists prepare their entries to the Second IOF-Alliance Osteoporosis Media Award, deadline June 15. Download the entry form at:
http://www.osteofound.org/activities/media_award/index.html

Journalists can view the Congress abstracts at: http://www.osteofound.org/wco/2002/abstracts.php

Deadline for journalists' registration: April 30